[Electrophysiologic research on the anti-arrhythmia properties of bonnecor--a new dibenzazepine derivative].
A new dibenzepin derivative, bonnecor, showed marked antiarrhythmic and antifibrillation properties in anesthetized cats. One and 2 mg/kg doses of the drug reduce cardiac assimilation of imposed ventricular electric stimuli, increase ventricular fibrillation threshold with a strong and lasting effect and prevent arrhythmias and fibrillation due to 10-minute occlusion and subsequent reperfusion of the anterior descending branch of the left coronary artery. Experimental holding of atrial trabecular membrane potential in a frog, in conditions of a double saccharose bridge, showed bonnecor, in 5 X 10(-7) and 1 X 10(-6) g/ml concentrations, to inhibit rapid sodium inflow and slow calcium inflow. It is expected that bonnecor can be used clinically to control critical arrhythmias and prevent sudden cardiac death.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D002415:Cats; D003984:Dibenzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006325:Heart Atria / Q000187:drug effects; D066298:In Vitro Techniques; D008012:Lidocaine / Q000627:therapeutic use; D008564:Membrane Potentials / Q000187:drug effects; D016293:Moricizine; D010640:Phenothiazines / Q000627:therapeutic use; D011893:Rana esculenta
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; D010640:Phenothiazines; D016293:Moricizine; D008012:Lidocaine; C048166:tiracizine
Elektrofiziologicheskoe issledovanie antiaritmicheskikh svoĭstv bonnekora--novogo proizvodnogo dibenzazepina.